Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTOR – AUC Control of Tacrolimus in Organ Recipients
2026-527107-22-00Phase 4Authorised
- Sponsor
- Oslo University Hospital
- Start
- Oct 2026
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in kidney transplant, sponsored by Oslo University Hospital. Primary endpoint: AUC0-12 (rich sampled). Planned start Oct 2026; status: authorised.
02
Drugs
tacrolimus
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2026-527107-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527107-22-00.